Centeon albumin market withdrawal costs RPR $44 mil.; consent decree allows operations to resume.
CENTEON ALBUMIN RECALL COSTS RHONE-POULENC RORER $44 MIL. IN CHARGES for fiscal 1996, the French drugmaker reported Jan. 27. RPR "incurred a significant cost during the second half of the year due to the recall of Centeon's Albuminar and the cost of lost business related to other Centeon products manufactured at this facility," the company said. Centeon is the blood products joint venture of RPR and Hoechst. Centeon's Kankakee, Ill. manufacturing facility resumed production of the blood products Jan. 22 under a consent decree with FDA ("The Pink Sheet" Jan. 27, T&G-3).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth